Kim Pettersson

List of Publications by Year
in descending order

115 papers	4,104 citations	109264 35 h-index	128225 60 g-index
115 all docs	115 docs citations	115 times ranked	3605 citing authors

#	Article	IF	Citations
1	Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clinical Chemistry, 1997, 43, 1379-1385.	1.5	234
2	Degradation of cardiac troponin I: implication for reliable immunodetection. Clinical Chemistry, 1998, 44, 2433-2440.	1.5	215
3	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in GÅ¶teborg, Sweden. BMC Medicine, 2008, 6, 19.	2.3	212
4	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. Journal of Clinical Oncology, 2010, 28, 2493-2498.	0.8	204
5	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Caseâ€“Control Study. European Urology, 2015, 68, 207-213.	0.9	120
6	Negative Interference in Cardiac Troponin I Immunoassays by Circulating Troponin Autoantibodies. Clinical Chemistry, 2005, 51, 839-847.	1.5	116
7	Associations Between Homocysteine, Bone Turnover, BMD, Mortality, and Fracture Risk in Elderly Women. Journal of Bone and Mineral Research, 2006, 22, 127-134.	3.1	103
8	Performance of fluorescent europium(III) nanoparticles and colloidal gold reporters in lateral flow bioaffinity assay. Analytical Biochemistry, 2012, 428, 31-38.	1.1	100
9	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. Journal of Urology, 1996, 156, 350-354.	0.2	99
10	Negative Interference in Cardiac Troponin I Immunoassays from a Frequently Occurring Serum and Plasma Component. Clinical Chemistry, 2003, 49, 1095-1104.	1.5	92
11	Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146. Clinical Chemistry, 2001, 47, 1415-1423.	1.5	82
12	Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate, 2001, 49, 101-109.	1.2	82
13	Autoantibodies against Cardiac Troponins. New England Journal of Medicine, 2005, 352, 98-100.	13.9	79
14	Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome. Clinical Chemistry, 1997, 43, 2323-2332.	1.5	73
15	Role of lectin microarrays in cancer diagnosis. Proteomics, 2016, 16, 1257-1265.	1.3	68
16	Intact Free Prostate-Specific Antigen and Free and Total Human Glandular KallikreinÂ2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(abâ€˜)2Fragments. Analytical Chemistry, 2006, 78, 7809-7815.	3.2	61
17	Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. Protein Science, 1998, 7, 259-269.	3.1	60
18	The Frequency of an Inactivating Point Mutation (566Câ†’T) of the Human Follicle-Stimulating Hormone Receptor Gene in Four Populations Using Allele-Specific Hybridization and Time-Resolved Fluorometry1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4338-4343.	1.8	60

#	Article	IF	Citations
19	Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA. Clinical Chemistry, 2000, 46, 1610-1618.	1.5	60
20	Dual-Label Time-resolved Immunofluorometric Assay of Free and Total Prostate-specific Antigen Based on Recombinant Fab Fragments. Clinical Chemistry, 2000, 46, 658-666.	1.5	59
21	Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum. Clinical Chemistry, 2000, 46, 198-206.	1.5	58
22	Characterization of Serum Tartrate-Resistant Acid Phosphatase and Development of a Direct Two-Site Immunoassay. Journal of Bone and Mineral Research, 1998, 13, 683-687.	3.1	55
23	Combined Inhibin and CA125 Assays in the Detection of Ovarian Cancer. Clinical Chemistry, 1999, 45, 651-658.	1.5	55
24	Comparison of Cardiac Troponin I Immunoassays Variably Affected by Circulating Autoantibodies. Clinical Chemistry, 2005, 51, 848-855.	1.5	54
25	Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone, 2005, 36, 786-792.	1.4	53
26	Autoantibodies to Cardiac Troponin Associate with Higher Initial Concentrations and Longer Release of Troponin I in Acute Coronary Syndrome Patients. Clinical Chemistry, 2009, 55, 938-945.	1.5	52
27	Development and Evaluation of Three Immunofluorometric Assays That Measure Different Forms of Osteocalcin in Serum. Clinical Chemistry, 2000, 46, 332-337.	1.5	50
28	Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Clinical Endocrinology, 1998, 49, 369-376.	1.2	47
29	Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2. Clinical Chemistry, 2004, 50, 1607-1617.	1.5	47
30	Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. Journal of Urology, 2002, 168, 1917-1922.	0.2	46
31	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS ONE, 2016, 11, e0155901.	1.1	43
32	Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies. Journal of Bone and Mineral Research, 1999, 14, 464-469.	3.1	42
33	Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. Journal of the National Cancer Institute, 2013, 105, 237-243.	3.0	42
34	The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. , 1998, 83, 2540-2547.		41
35	Development of Highly Fluorescent Detection Reagents for the Construction of Ultrasensitive Immunoassays. Analytical Chemistry, 2001, 73, 1521-1529.	3.2	38
36	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	2.5	36

#	Article	IF	Citations
37	Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate, 2005, 63, 13-18.	1.2	35
38	Clinical Significance of Troponin I Efflux and Troponin Autoantibodies in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2008, 14, 481-488.	0.7	35
39	Troponin-Specific Autoantibody Interference in Different Cardiac Troponin I Assay Configurations. Clinical Chemistry, 2012, 58, 1040-1048.	1.5	35
40	Quantitative real-time RT-PCR assay for PCA3. Clinical Biochemistry, 2008, 41, 103-108.	0.8	34
41	An interfering component in cardiac troponin I immunoassaysâ€"Its nature and inhibiting effect on the binding of antibodies against different epitopes. Clinical Biochemistry, 2004, 37, 472-480.	0.8	33
42	Epitope mapping of nine monoclonal antibodies against osteocalcin: Combinations into two-site assays affect both assay specificity and sample stability. Journal of Bone and Mineral Research, 1996, 11, 1165-1175.	3.1	33
43	Rapid and sensitive cardiac troponin I immunoassay based on fluorescent europium(III)-chelate-dyed nanoparticles. Clinica Chimica Acta, 2012, 414, 70-75.	0.5	33
44	Structural investigation of the alphaâ€1â€antichymotrypsin: Prostateâ€specific antigen complex by comparative model building. Protein Science, 1996, 5, 836-851.	3.1	32
45	Effects of blood sample anticoagulants on lateral flow assays using luminescent photon-upconverting and Eu(III) nanoparticle reporters. Analytical Biochemistry, 2016, 492, 13-20.	1.1	31
46	A Nanoparticle-Based Approach for the Detection of Extracellular Vesicles. Scientific Reports, 2019, 9, 10038.	1.6	30
47	Point-of-Care Time-resolved Immunofluorometric Assay for Human Pregnancy-associated Plasma Protein A: Use in First-Trimester Screening for Down Syndrome. Clinical Chemistry, 2002, 48, 473-483.	1.5	29
48	High-sensitivity lateral flow immunoassay with a fluorescent lanthanide nanoparticle label. Journal of Immunological Methods, 2019, 465, 39-44.	0.6	29
49	Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS ONE, 2019, 14, e0219480.	1.1	26
50	Identification of novel proteolytic forms of osteocalcin in human urine. Biochemical and Biophysical Research Communications, 2003, 306, 973-980.	1.0	25
51	Upconverting nanoparticle reporterâ€"based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen. Analytical and Bioanalytical Chemistry, 2021, 413, 967-978.	1.9	25
52	Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection. Clinical Biochemistry, 2017, 50, 54-61.	0.8	24
53	The Proportion of Carboxylated to Total or Intact Osteocalcin in Serum Discriminates Warfarin-Treated Patients from Control Subjects. Journal of Bone and Mineral Research, 1999, 14, 555-560.	3.1	23
54	Epitope Specificity and IgG Subclass Distribution of Autoantibodies to Cardiac Troponin. Clinical Chemistry, 2013, 59, 512-518.	1.5	23

#	Article	IF	Citations
55	Glycovariant-based lateral flow immunoassay to detect ovarian cancerâ€“associated serum CA125. Communications Biology, 2020, 3, 460.	2.0	23
56	Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Research in Cardiology, 2000, 95, 413-417.	2.5	22
57	A comparison of capture antibody fragments in cardiac troponin I immunoassay. Clinical Biochemistry, 2013, 46, 963-968.	0.8	22
58	Lateral flow immunoassay with upconverting nanoparticleâ€based detection for indirect measurement of interferon response by the level of MxA. Journal of Medical Virology, 2017, 89, 598-605.	2.5	22
59	Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. , 1997, 31, 84-90.		21
60	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. The Histochemical Journal, 1999, 31, 45-52.	0.6	21
61	Autoantibodies to cardiac troponin in acute coronary syndromes. Clinica Chimica Acta, 2010, 411, 1793-1798.	0.5	21
62	A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Clinical Chemistry, 2016, 62, 1390-1400.	1.5	21
63	Global expression of AMACR transcripts predicts risk for prostate cancer â€“ a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urology, 2016, 16, 10.	0.6	19
64	Cardiac troponin elevations in marathon runners. Role of coronary atherosclerosis and skeletal muscle injury. The MaraCat Study. International Journal of Cardiology, 2019, 295, 25-28.	0.8	19
65	Sensitive LH and FSH assays for monitoring low serum levels in men undergoing steroidal contraception. Clinical Endocrinology, 2001, 55, 331-339.	1.2	18
66	Double-Antigen Lateral Flow Immunoassay for the Detection of Anti-HIV-1 and -2 Antibodies Using Upconverting Nanoparticle Reporters. Sensors, 2021, 21, 330.	2.1	18
67	Elevation of cardiac troponins measured after recreational resistance training. Clinical Biochemistry, 2015, 48, 803-806.	0.8	16
68	A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Gynecologic Oncology, 2020, 156, 689-694.	0.6	16
69	Sensitive and quantitative detection of cardiac troponin I with upconverting nanoparticle lateral flow test with minimized interference. Scientific Reports, 2021, 11, 18698.	1.6	16
70	Simultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay. Journal of Nanobiotechnology, 2010, 8, 27.	4.2	15
71	Autoantibody prevalence with an improved immunoassay for detecting cardiac troponin-specific autoantibodies. Clinical Chemistry and Laboratory Medicine, 2014, 52, 273-9.	1.4	15
72	Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. Urology, 2014, 83, 511.e1-511.e7.	0.5	15

#	Article	IF	Citations
73	Simultaneous Quantification of Prostate-specific Antigen and Human Glandular Kallikrein 2 mRNA in Blood Samples from Patients with Prostate Cancer and Benign Disease. Clinical Chemistry, 2002, 48, 1265-1271.	1.5	14
74	Demonstration of the Predominant Urine Osteocalcin Fragments Detectable by Two-Site Immunoassays. Journal of Bone and Mineral Research, 1999, 14, 431-438.	3.1	12
75	Skeletal troponin I cross-reactivity in different cardiac troponin I assay versions. Clinical Biochemistry, 2015, 48, 313-317.	0.8	12
76	Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancerâ€“Associated CA125 from Benign Sources. journal of applied laboratory medicine, The, 2019, 4, 299-310.	0.6	12
77	Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. Journal of Urology, 2002, 168, 1917-22.	0.2	12
78	Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. Clinical Biochemistry, 2007, 40, 111-118.	0.8	11
79	Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. Clinical Biochemistry, 2013, 46, 670-674.	0.8	11
80	HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma. Acta OncolÃ³gica, 2020, 59, 1461-1468.	0.8	11
81	Ultrasensitive and Robust Point-of-Care Immunoassay for the Detection of Plasmodium falciparum Malaria. Analytical Chemistry, 2020, 92, 15766-15772.	3.2	11
82	Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing. Clinical Chemistry, 2001, 47, 703-711.	1.5	10
83	Intact and Internally Cleaved Free Prostate-Specific Antigen in Patients With Prostate Cancer With Different Pathologic Stages and Grades. Urology, 2011, 77, 1009.e1-1009.e8.	0.5	10
84	Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys145 or Lys146 from fPSA without internal cleavages at Lys145 or Lys146. Journal of Immunological Methods, 2011, 369, 74-80.	0.6	10
85	Can one blood draw replace transrectal ultrasonographyâ€estimated prostate volume to predict prostate cancer risk?. BJU International, 2013, 112, 602-609.	1.3	10
86	Anti-HCV immunoassays based on a multiepitope antigen and fluorescent lanthanide chelate reporters. Journal of Virological Methods, 2016, 228, 67-73.	1.0	9
87	Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Molecular Aspects of Medicine, 2020, 72, 100831.	2.7	9
88	Exploratory Analysis of CA125-MGL and â€“STn Glycoforms in the Differential Diagnostics of Pelvic Masses. journal of applied laboratory medicine, The, 2020, 5, 263-272.	0.6	9
89	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp>, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 465-477.	1.9	9
90	Detection of bladder cancer with aberrantly fucosylated ITGA3. Analytical Biochemistry, 2021, 628, 114283.	1.1	9

#	Article	IF	Citations
91	Novel sensitive cardiac troponin I immunoassay free from troponin I-specific autoantibody interference. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1041-8.	1.4	8
92	Stratification of aggressive prostate cancer from indolent diseaseâ€"Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 255.e15-255.e22.	0.8	8
93	Identification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library. Clinical Biochemistry, 2016, 49, 472-479.	0.8	8
94	Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human Molecular Genetics, 2020, 29, 1581-1591.	1.4	8
95	Array-in-well platformâ€"based multiplex assay for the simultaneous detection of anti-HIV- and treponemal-antibodies, and Hepatitis B surface antigen. Journal of Immunological Methods, 2016, 429, 21-27.	0.6	7
96	A Dual-Label Immunofluorometric Assay for Human Osteocalcin. Journal of Bone and Mineral Research, 1998, 13, 1183-1190.	3.1	6
97	Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. BMC Urology, 2015, 15, 88.	0.6	6
98	Diagnostic potential of nanoparticle aided assays for <scp>MUC16</scp> and <scp>MUC1</scp> glycovariants in ovarian cancer. International Journal of Cancer, 2022, 151, 1175-1184.	2.3	6
99	Europium Nanoparticle-Based High Performing Immunoassay for the Screening of Treponemal Antibodies. PLoS ONE, 2013, 8, e84050.	1.1	5
100	All-in-one dry-reagent time-resolved immunofluorometric assay for the rapid detection of HIV-1 and -2 infections. Journal of Virological Methods, 2015, 226, 52-59.	1.0	5
101	Europium nanoparticle-based simple to perform dry-reagent immunoassay for the detection of hepatitis B surface antigen. Journal of Virological Methods, 2016, 229, 66-69.	1.0	5
102	Extension of dynamic range of sensitive nanoparticle-based immunoassays. Analytical Biochemistry, 2014, 446, 82-86.	1.1	4
103	Chimeric recombinant antibody fragments in cardiac troponin I immunoassay. Clinical Biochemistry, 2015, 48, 347-352.	0.8	4
104	Direct Immunoassay for Free Pregnancy-Associated Plasma Protein A (PAPP-A). journal of applied laboratory medicine, The, 2018, 3, 438-449.	0.6	4
105	Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys145â€"Lys146 internally cleaved forms. Journal of Immunological Methods, 2015, 422, 72-79.	0.6	3
106	Microparticleâ^'based platform for point-of-care immunoassays. Analytical Biochemistry, 2018, 548, 66-68.	1.1	3
107	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€Learning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	1.9	3
108	Prospective validation of microseminoproteinâ€Î²2 added to the 4Kscore in predicting highâ€grade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	1.3	3

#	Article	IF	Citations
109	Potentially pathogenic circulating autoantibodies to cardiac troponin are present in hemodialysis patients. Hemodialysis International, 2017, 21, 519-523.	0.4	1
110	Evaluation of a New Skeletal Troponin I Assay in Patients with Idiopathic Inflammatory Myopathies. journal of applied laboratory medicine, The, 2020, 5, 320-331.	0.6	1
111	Three two-site apoA-I immunoassays using phage expressed detector antibodies â€“ Preliminary clinical evaluation with cardiac patients. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113772.	1.4	1
112	The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer, 1998, 83, 2540-2547.	2.0	1
113	Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. Journal of Histochemistry and Cytochemistry, 2016, 64, 311-322.	1.3	0
114	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. journal of applied laboratory medicine, The, 2019, 3, 1014-1021.	0.6	0
115	Free PAPP-A as a biomarker: heparin-induced release is not related to coronary atherosclerotic burden. Clinical Chemistry and Laboratory Medicine, 2019, 57, e155-e158.	1.4	0